| 摘要 |
Process for stimulating a lymphocyte proliferative response in humans is claimed comprising treatment with a recombinant HIV portion of an ITLV-III protein selected from R10, PB1, 590 and KH1. Novel recombinant HTLV-III fusion proteins denoted R10, PB1, 590, KH1 and the HIV portion of each of these proteins are useful in the diagnosis, prophylaxis or therapy of AIDS. The proteins are esp. useful for prepg vaccines for the HTLV-III virus. Plasmid pR10 contains 1275 bp of DNA encoding the HTLV-III env gene from the KpnI site to the BglII site. This plasmid can be used to produce the novel recombinant HTLV-III 95kD fusion protein R10. Plasmid pPB1 contains 540 bp of DNA encoding the HTLV-III env gene from the PVuII site to the BglII site. This plasmid can be used to produce the novel recombinant HTLV-III 26 kD fusion protein PB1. Plasmid p590 contains 1055 bp of DNA encoding the HTLV-III env gene from the PVuII site to the Hind III site. This plasmid can be used to produce the novel recombinant HTLV-III 86kD protein 590. Plasmid pKH1 contains 1830 bp of DNA encoding the HTLV-III gene from the KpnI site to the Hind III site. This plasmid can be used to produce the novel recombinant HTLV-III 70kD protein KH1. Oligonucleotide-directed site-specific mutagenesis can be used to eliminate the non-HTLV-III amino acids blanking the env gene fusion proteins. |
